OSTX Valuation
OS Therapies Inc
$
2.210
- Overview
- Forecast
- Valuation
- Earnings
OSTX Relative Valuation
OSTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OSTX is overvalued; if below, it's undervalued.
Historical Valuation
OS Therapies Inc (OSTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -6.16. The fair price of OS Therapies Inc (OSTX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.17 USD , OS Therapies Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：2.17
Fair
Undervalued
-3.68
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
OS Therapies Inc. (OSTX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward EV/EBITDA of 0.00 falls within the Strongly Undervalued range.
-3.91
EV/EBIT
OS Therapies Inc. (OSTX) has a current EV/EBIT of -3.91. The 5-year average EV/EBIT is 2.34. The thresholds are as follows: Strongly Undervalued below -3.57, Undervalued between -3.57 and -0.62, Fairly Valued between 5.30 and -0.62, Overvalued between 5.30 and 8.26, and Strongly Overvalued above 8.26. The current Forward EV/EBIT of -3.91 falls within the Strongly Undervalued range.
0.00
PS
OS Therapies Inc. (OSTX) has a current PS of 0.00. The 5-year average PS is 1.67. The thresholds are as follows: Strongly Undervalued below -0.31, Undervalued between -0.31 and 0.68, Fairly Valued between 2.66 and 0.68, Overvalued between 2.66 and 3.64, and Strongly Overvalued above 3.64. The current Forward PS of 0.00 falls within the Undervalued range.
0.00
P/OCF
OS Therapies Inc. (OSTX) has a current P/OCF of 0.00. The 5-year average P/OCF is 0.68. The thresholds are as follows: Strongly Undervalued below -0.61, Undervalued between -0.61 and 0.04, Fairly Valued between 1.32 and 0.04, Overvalued between 1.32 and 1.96, and Strongly Overvalued above 1.96. The current Forward P/OCF of 0.00 falls within the Undervalued range.
0.00
P/FCF
OS Therapies Inc. (OSTX) has a current P/FCF of 0.00. The 5-year average P/FCF is 1.17. The thresholds are as follows: Strongly Undervalued below -0.50, Undervalued between -0.50 and 0.33, Fairly Valued between 2.00 and 0.33, Overvalued between 2.00 and 2.84, and Strongly Overvalued above 2.84. The current Forward P/FCF of 0.00 falls within the Undervalued range.
OS Therapies Inc (OSTX) has a current Price-to-Book (P/B) ratio of 13.20. Compared to its 3-year average P/B ratio of -25.77 , the current P/B ratio is approximately -151.24% higher. Relative to its 5-year average P/B ratio of -25.77, the current P/B ratio is about -151.24% higher. OS Therapies Inc (OSTX) has a Forward Free Cash Flow (FCF) yield of approximately -16.46%. Compared to its 3-year average FCF yield of -13.73%, the current FCF yield is approximately 19.90% lower. Relative to its 5-year average FCF yield of -13.73% , the current FCF yield is about 19.90% lower.
13.20
P/B
Median3y
-25.77
Median5y
-25.77
-16.46
FCF Yield
Median3y
-13.73
Median5y
-13.73
Competitors Valuation Multiple
The average P/S ratio for OSTX's competitors is 0.17, providing a benchmark for relative valuation. OS Therapies Inc Corp (OSTX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OSTX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OSTX in the past 1 year is driven by Unknown.
People Also Watch
AIXI
Xiao-I Corp
1.710
USD
+3.01%
MATH
Metalpha Technology Holding Ltd
3.540
USD
+5.67%
KOSS
Koss Corp
5.770
USD
+1.58%
INUV
Inuvo Inc
3.450
USD
0.00%
FBLG
Fibrobiologics Inc
0.535
USD
+1.90%
TORO
Toro Corp
3.070
USD
-0.32%
NEUE
NeueHealth Inc
6.639
USD
-1.94%
CRT
Cross Timbers Royalty Trust
7.800
USD
+0.52%
SOTK
Sono-Tek Corp
4.090
USD
-0.24%
MDBH
MDB Capital Holdings LLC
3.550
USD
0.00%
FAQ
Is OS Therapies Inc (OSTX) currently overvalued or undervalued?
OS Therapies Inc (OSTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -6.16. The fair price of OS Therapies Inc (OSTX) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 2.17 USD , OS Therapies Inc is Undervalued By Fair .
What is OS Therapies Inc (OSTX) fair value?
How does OSTX's valuation metrics compare to the industry average?
What is the current P/B ratio for OS Therapies Inc (OSTX) as of Sep 19 2025?
What is the current FCF Yield for OS Therapies Inc (OSTX) as of Sep 19 2025?
What is the current Forward P/E ratio for OS Therapies Inc (OSTX) as of Sep 19 2025?
